Showing 2,021 - 2,040 results of 17,627 for search '"The Progressive"', query time: 0.28s Refine Results
  1. 2021
  2. 2022
  3. 2023
  4. 2024
  5. 2025
  6. 2026
  7. 2027
  8. 2028
  9. 2029

    CircUCK2(2,3) promotes cancer progression and enhances synergistic cytotoxicity of lenvatinib with EGFR inhibitors via activating CNIH4–TGFα–EGFR signaling by Xindong Wei, Anfeng Si, Shuai Zhao, Yi Fu, Jilei Li, Kedeerya Aishanjiang, Yujie Ma, Chang Yu, Bo Yu, Chunhong Cui, Hui Wang, Xianming Kong, Shibo Li, Xiaoni Kong, Ying Tong, Hailong Wu

    Published 2025-01-01
    “…Abstract Background Circular (circ)RNAs have emerged as crucial contributors to cancer progression. Nonetheless, the expression regulation, biological functions, and underlying mechanisms of circRNAs in mediating hepatocellular carcinoma (HCC) progression remain insufficiently elucidated. …”
    Get full text
    Article
  10. 2030

    Research progress of Traditional Chinese Medicine characteristic nursing techniques for patients with pancreatic cancer (中医特色护理技术在胰腺癌中的应用研究进展) by GAO Donghua (高冬华), WANG Guiting (王贵婷), ZHANG Xinhui (张鑫辉), TIAN Wanqin (田婉琴), Tang Ling (唐玲)

    Published 2021-11-01
    “…Its clinical manifestations are mainly abdominal discomfort and dull pain, often accompanied by loss of appetite, loss of body shape and obstructive jaundice. With the progress of the disease, the quality of life, work and survival of patients are seriously affected. …”
    Get full text
    Article
  11. 2031

    Multidose Streptozotocin Induction of Diabetes in BALB/c Mice Induces a Dominant Oxidative Macrophage and a Conversion of TH1 to TH2 Phenotypes During Disease Progression by Naxin Sun, Guiwen Yang, Heng Zhao, Huub F. J. Savelkoul, Liguo An

    Published 2005-01-01
    “…We found that peritoneal Mp appeared as an “incomplete” OMp phenotype with decreased icGSH along with disease progression. The OMp showed reduced TNF-α, IL-12, and NO production as well as defective phagocytosis activity compared to nondiabetic controls; however, there was no significant difference with IL-6 production. …”
    Get full text
    Article
  12. 2032

    PReventing Idiopathic SCOliosis PROgression (PRISCOPRO): A protocol for a quadruple-blinded, randomized controlled trial comparing 3D designed Boston brace to standard Boston brace. by Elias Diarbakerli, Anastasios Charalampidis, Allan Abbott, Paul Gerdhem

    Published 2021-01-01
    “…Treatment strategies aim to halt progression of the curve. Patients are treated mainly with thoracolumbosacral orthosis (TLSO) if indicated. …”
    Get full text
    Article
  13. 2033

    MRTX1133 attenuates KRASG12D mutated-colorectal cancer progression through activating ferroptosis activity via METTL14/LINC02159/FOXC2 axis by Junwei Zou, Xiuhua Shi, Zhaoying Wu, Siyuan Zuo, Xiaolei Tang, Hailang Zhou, Yong Huang

    Published 2025-02-01
    “…Emerging evidence indicates that long non-coding RNAs (lncRNAs) are crucial in the carcinogenesis and progression of various cancers, regulating multiple biological processes but the link between KRASG12D mutations and lncRNAs in CRC remains unclear. …”
    Get full text
    Article
  14. 2034
  15. 2035
  16. 2036
  17. 2037
  18. 2038

    Aging-enhanced autophagy activity promotes fibrotic progression via the TGF-β2/Smad signaling pathway in trabecular meshwork cells—a new insight from POAG by Jin Han, Jun Wang, Ling Shen, Yiting Cai, Xuze Wang, Ailixiati Wumaier, Wei Chen, Wei Han

    Published 2025-01-01
    “…Further investigation showed that enhanced autophagy activity promoted fibrotic progression via activation of the TGF-β2/Smad signaling pathway. …”
    Get full text
    Article
  19. 2039
  20. 2040

    Clinical Significance of the Relationship between Progression-Free Survival or Postprogression Survival and Overall Survival in Patients with Extensive Disease-Small-Cell Lung Cancer Treated with Carboplatin plus Etoposide by Hisao Imai, Keita Mori, Nodoka Watase, Sakae Fujimoto, Kyoichi Kaira, Masanobu Yamada, Koichi Minato

    Published 2016-01-01
    “…Type of relapse (refractory/sensitive) and the number of regimens administered after disease progression after the first-line chemotherapy were both significantly associated with PPS (p<0.05). …”
    Get full text
    Article